Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer
Conditions
- Differentiated Thyroid Gland Carcinoma
- Malignant Adrenal Gland Pheochromocytoma
- Malignant Paraganglioma
- Thyroid Gland Medullary Carcinoma
Interventions
- PROCEDURE: Computed Tomography
- PROCEDURE: Dual X-ray Absorptiometry
- PROCEDURE: Physical Examination
- OTHER: Quality-of-Life Assessment
- OTHER: Questionnaire Administration
- DRUG: Cabozantinib
- DRUG: Lenvatinib
Sponsor
M.D. Anderson Cancer Center
Collaborators